Gibco™ OpTmizer™ CTS™ T-Cell Expansion SFM has been developed for the growth and expansion of human T lymphocytes. OpTmizer™ CTS™ T-Cell Expansion medium is a complete serum-free and xeno-free 1X medium consisting of OpTmizer™ T-Cell Expansion Basal Medium (1 L bag) and OpTmizer™ T-Cell Expansion Supplement (26 mL), which are mixed together prior to use.

• Maintains similar phenotype and function as T-cells cultured in conventional serum supplemented medium
• Consistent performance in supporting T-cell expansion
• Supports high density cultures in static and WAVE Bioreactor™ cultures
• Be ready for clinical research with this cGmP manufactured formula and support documentation

Versatile T Cell Culture Media
OpTmizer™ CTS™ T-Cell Expansion SFM is designed to give results equivalent to conventional serum-supplemented media. However, if desired, 2% heat-inactivated human serum (Cat. No. 34005-100) may be added to the medium to enhance viability and expansion. The use of serum, and the amount required, should be determined empirically depending on the specific T-cell culture application.

Ready for T Cell Expansion
OpTmizer™ CTS™ T-Cell Expansion SFM is designed for the expansion of human T-cells permitting CD3+ densities of >3x10⁶ cells/mL in static conditions and >2x10⁷ cells/mL in WAVE bags. Results may vary depending on the T-cell subset (e.g., Ag-specific cells). Conditions for specific T-cell culture applications should be determined empirically.

Stability of Complete Media
Complete OpTmizer™ CTS™ T-Cell Expansion SFM (basal, supplement, and L-glutamine) is stable for 4 weeks when stored in the dark at 2–8°C.

Simplify Your Transition into Clinical Research
The Gibco™ Cell Therapy Systems (CTS™) brand offers a broad array of products for use in cell therapy applications, including media, reagents, growth factors, enzymes, cell selection/expansion reagents, and devices. Gibco™ CTS™ products deliver:
• Reduced burden in qualifying reagents
• Appropriate certificates of analyses and origin included
• Convenient access to our Drug Master File (DMF)